this is my journL CLUB PRESENTATION CAN YOU CHECK THIS AND PREPARE SOM

this is my journL CLUB PRESENTATION CAN YOU CHECK THIS AND PREPARE SOME QUESTIONS AND ANSWERS THAT COUYLD BE ASKED TO ME BT MTY CONSULTANTS

Reading File

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') print('Number of slides:', len(prs.slides)) for i, slide in enumerate(prs.slides, 1): print('---- SLIDE', i, '----') for shape in slide.shapes: if shape.has_text_frame and shape.text_frame.text.strip(): print(shape.text_frame.text) if shape.has_table: tbl = shape.table for row in tbl.rows: print(' | '.join(cell.text for cell in row.cells)) "

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): if i in [7,8,10,12,22,23,24]: print('---- SLIDE', i, '----') for shape in slide.shapes: print(shape.shape_type, shape.name) if shape.has_text_frame: print(' TEXT:', shape.text_frame.text) if shape.has_table: tbl = shape.table for row in tbl.rows: print(' ROW:', ' | '.join(cell.text for cell in row.cells)) "

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && mkdir -p extracted_images && python3 -c " from pptx import Presentation import os prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): for shape in slide.shapes: if shape.shape_type == 13: # PICTURE image = shape.image ext = image.ext fname = f'extracted_images/slide{i}_{shape.shape_id}.{ext}' with open(fname, 'wb') as f: f.write(image.blob) print('saved', fname) " ls -la extracted_images/

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82 && python3 -c " from pptx import Presentation prs = Presentation('jc august 26.pptx') for i, slide in enumerate(prs.slides, 1): if i in [8,10,12]: print('SLIDE', i, 'shape count:', len(slide.shapes)) for shape in slide.shapes: print(' ', shape.shape_type, shape.name, getattr(shape,'width',None)) "

Reading File

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82/extracted_images && python3 -c " from PIL import Image for f in ['slide9_4.png','slide23_7.png','slide24_7.png','slide24_9.png']: im = Image.open(f) im.thumbnail((900,900)) im.save(f.replace('.png','_small.jpg'), 'JPEG', quality=70) " ls -la *_small.jpg

Running Command

cd /tmp/workspace/attachments/2b22984f-22f7-4b4c-9073-c5a617ee1a82/extracted_images && python3 -c " from PIL import Image for f in ['slide9_4.png','slide23_7.png','slide24_7.png','slide24_9.png']: im = Image.open(f).convert('RGB') im.thumbnail((900,900)) im.save(f.replace('.png','_small.jpg'), 'JPEG', quality=70) " ls -la *_small.jpg

Reading File

Excellent, this gives full Table 1 data. Now let's check slides 23 and 24 (second study's results tables).

Reading File

Finding Sources

Searching PubMed

"BCG vaccine" AND leprosy

Searching PubMed

"anti-PGL-I" leprosy diagnosis

I reviewed both papers in your journal club deck (BCG vaccination in childhood leprosy - PGIMER; and Slit Skin Smear vs Anti-PGL-I serology - Egypt). Here's a full set of likely consultant questions with model answers, organized by theme. I also pulled one directly relevant recent meta-analysis (PMID 39632641) you should know about in case they push on "is there newer evidence."

Paper 1: BCG Vaccination in Childhood Leprosy (PGIMER, Chandigarh)

Q1. Why is a "BCG scar" used as a proxy for vaccination status, and what is wrong with that? A: Scar presence/absence was used because vaccination cards/records were unavailable retrospectively. It's imperfect - scar formation fails in 1-20% of truly vaccinated people (poor technique, subcutaneous injection, host factors), and scars can occasionally fade over years. So some "unvaccinated" (no-scar) children may actually have received BCG, which would bias results toward the null (dilute the protective effect seen).

Q2. This is a retrospective observational study - what are the inherent limitations, and why wasn't a cohort/case-control design used? A: Retrospective design is subject to recall/selection bias, missing or incomplete records (they explicitly excluded incomplete records, which itself introduces selection bias), no randomization, and cannot establish causality - only association. A prospective cohort comparing BCG card-confirmed vaccinated vs unvaccinated children followed from leprosy contact/exposure would be ideal but is logistically very difficult given leprosy's long incubation period (years).

Q3. How was the diagnosis of leprosy confirmed, and what are the WHO cardinal signs? A: Diagnosis required ≥1 of: (1) definite sensory loss in a hypopigmented/erythematous patch, (2) thickened/enlarged peripheral nerve with sensory loss and/or motor weakness, (3) demonstration of acid-fast bacilli on slit-skin smear. Histopathology was also done at baseline/end of treatment as supportive routine care in most cases.

Q4. What is the Ridley-Jopling classification and how does it differ from the WHO operational classification? A: Ridley-Jopling is an immunopathological spectrum: TT (tuberculoid) - BT - BB (borderline) - BL - LL (lepromatous), reflecting a gradient from strong cell-mediated immunity (TT) to weak CMI/high bacillary load (LL), plus PNL (pure neuritic leprosy). WHO's operational classification (for field/treatment purposes) is simpler: paucibacillary (PB, ≤5 lesions, smear-negative) vs multibacillary (MB, >5 lesions or smear-positive) - used to decide MDT duration/regimen.

Q5. What was the key statistically significant finding, and does it make biological sense? A: Absence of a BCG scar correlated significantly with predisposition to multibacillary disease - 10/11 unvaccinated children were at the lepromatous pole (5 BL, 5 LL). Biologically this fits: BCG's immunomodulatory/Th1-priming effect is thought to shift the immune response toward the tuberculoid (paucibacillary) pole and away from the anergic lepromatous pole, similar to its heterologous, non-specific innate-training effects seen with other mycobacterial antigens.

Q6. What was the actual p-value/statistical test used for that finding, and was multivariate adjustment for confounders (age, nutrition, contact exposure) done? A: The slide doesn't explicitly show the p-value or the test (likely chi-square/Fisher's exact given small cell counts) - you should verify this directly from the paper's results/table before presenting, since with an unvaccinated group of only 11, cell counts are very small and a consultant may ask you to justify use of Fisher's exact test versus chi-square, and whether confounders (nutritional status, degree of household contact/bacillary exposure, HLA/genetic susceptibility) were adjusted for. Based on the slide content alone, no multivariate adjustment was mentioned - this is worth flagging as a limitation if true.

Q7. Why do BT-spectrum patients show more persistent skin lesions (7/11, 63.6%) even though tuberculoid disease is considered "milder"? A: BT is immunologically unstable - it lies close to the midpoint of the spectrum and is prone to "downgrading" or delayed clinical/histological resolution even after adequate MDT, because residual granulomatous inflammation and nerve involvement can persist longer than the bacillary clearance. This is different from LL, where lesions may look diffuse but are more histologically stable to therapy despite higher bacillary index.

Q8. Why did the proportion of childhood leprosy (4.62%) not show a clear decreasing trend compared to the 2001-2011 study (4.8%)? A: This suggests transmission is ongoing and elimination programs (post-2005 "elimination" declaration in India) have plateaued rather than continuing to decline - possibly due to under-detection, reduced active case-finding after leprosy was "eliminated" as a public health problem (prevalence <1/10,000), and reduced surveillance funding, not necessarily true reduction in transmission.

Q9. Sample size was only 50 - was a power calculation done? Can you draw firm conclusions on reactions/disability from such small numbers? A: No power calculation is mentioned; this is explicitly listed as a limitation. With only 6 reaction cases and 11 disability cases total, subgroup comparisons (e.g., reactions in vaccinated vs unvaccinated) have very wide confidence intervals and limited statistical power - findings should be considered hypothesis-generating, not confirmatory.

Q10. Is there any more recent, larger-scale evidence on BCG's protective efficacy against leprosy specifically (not just TB)? A: Yes - a 2024 systematic review and meta-analysis of RCTs, "Efficacy of leprosy vaccines across the globe" (Dasgupta et al., Indian Journal of Medical Research, PMID 39632641), specifically pooled trial data on BCG and other candidate vaccines (e.g., MIP) against leprosy. Worth mentioning if a consultant asks about the strength of evidence beyond this single retrospective study - it would let you show you've looked beyond the assigned paper.

Q11. What does "MIP" refer to, mentioned in your conclusion? A: Mycobacterium indicus pranii - an alternative immunoprophylactic/immunotherapeutic mycobacterial vaccine studied in India as an adjunct to BCG or MDT for leprosy, particularly of interest for household contacts.

Paper 2: SSS vs Anti-PGL-I Serology

Q12. Why is slit-skin smear (SSS) considered a poor standalone test, and why is it still the WHO-recognized cardinal sign despite low sensitivity? A: SSS sensitivity is low (especially in paucibacillary/early disease with low bacillary load) and is highly technique- and reader-dependent. It remains the WHO cardinal sign because it is specific, cheap, requires no advanced infrastructure, and directly demonstrates the organism - important for field-level programs in resource-limited, high-burden settings even though it misses early/PB cases.

Q13. Why did all paucibacillary (TT and BT) cases test negative on SSS in this study - doesn't that undermine SSS's utility entirely? A: PB/tuberculoid-spectrum disease has a low bacillary load by definition (strong cell-mediated immunity controls the organism), so acid-fast bacilli are often below the detection threshold of smear microscopy. This is an expected and previously reported finding, not a flaw in technique - it's precisely why serology (or PCR) is proposed as an adjunct for these smear-negative-but-clinically-suspicious cases.

Q14. Explain what Anti-PGL-I (phenolic glycolipid-I) is and why IgM against it is used diagnostically. A: PGL-I is a species-specific glycolipid in the M. leprae cell wall. High bacillary loads (MB/LL disease) generate a strong IgM antibody response to PGL-I, so titers correlate with bacillary burden - hence higher sensitivity in MB and lower in PB (fewer bacilli, weaker antibody response). It is a marker of exposure/bacillary load, not necessarily of active clinical disease, so it can also be positive in some healthy household contacts.

Q15. How do you interpret the ROC curve findings, and what does AUC tell you here? A: The ROC curve plots sensitivity vs (1-specificity) across cutoffs for each test. In their PB-diagnosis ROC comparison, the anti-PGL-I curve is above and to the left of the SSS curve, meaning better discrimination (higher AUC) - anti-PGL-I identifies more true PB cases at a given false-positive rate. If asked for you exact AUC figures, note the slide/table with AUC/95% CI wasn't included in your extracted excerpt - check the paper's ROC statistics table before presenting exact values.

Q16. Why were patients with lepra reactions and those already treated >3 months excluded? A: Reactions (Type 1/Type 2 ENL) alter the local immune/inflammatory picture and can transiently affect antibody titers and clinical/histological findings, confounding diagnostic accuracy assessment. Prior treatment reduces bacillary load and antibody titers, which would artificially lower SSS/serology positivity and bias sensitivity estimates downward - excluding them isolates "de novo diagnostic performance."

Q17. This is a cross-sectional study - what does that mean for causal or prognostic claims, and could there be spectrum bias? A: Cross-sectional design only tells you diagnostic performance at one time point in patients already clinically suspected of leprosy (not a general population screen), so sensitivity/specificity figures may not generalize to asymptomatic contacts or population screening. Spectrum bias is a real concern here - if their sample was weighted toward advanced/MB cases, sensitivity of both tests would appear inflated relative to a true early-detection population.

Q18. Why did the study restrict serology to IgM anti-PGL-I only, and would testing IgG or combined isotypes change the results? A: IgM is the dominant/classic isotype used because it best reflects bacillary load in most studies, and assay kits are typically IgM-based. IgG or IgA anti-PGL-I, or combined isotype panels, have been explored in other studies (e.g., to differentiate leprosy patients from exposed but healthy contacts) and might improve sensitivity/specificity further - the authors themselves list "restriction to IgM only" as a limitation.

Q19. Practically, how would you use both tests together in a peripheral health center? A: Use SSS as the first-line, specific confirmatory test (per WHO), and reserve anti-PGL-I serology as an adjunct for smear-negative but clinically-suspicious (especially PB) cases to avoid missing early disease, and potentially for screening household contacts. A sequential/parallel testing strategy improves overall sensitivity without sacrificing the specificity SSS provides.

Cross-cutting / General Questions (likely from both papers)

Q20. What's the difference between a systematic review/meta-analysis and single observational studies like these - how much weight should we give this evidence? A: Both papers are single-center, non-randomized studies (retrospective cohort and cross-sectional respectively) - lower on the evidence hierarchy than RCTs or meta-analyses. They generate hypotheses and are useful for local epidemiology and test-performance estimates, but confirmatory conclusions (e.g., "BCG protects against MB leprosy") need larger, ideally prospective, multi-center data.

Q21. Type 1 vs Type 2 (ENL) lepra reactions - what's the difference? A: Type 1 (reversal) reactions occur in borderline (BT/BB/BL) disease due to abrupt increase in cell-mediated immunity against M. leprae antigens, causing existing lesions to become inflamed/edematous, with possible new nerve damage - not vasculitic. Type 2 (Erythema Nodosum Leprosum, ENL) occurs in BL/LL (MB) disease, is immune-complex mediated (Type III hypersensitivity), and presents with crops of tender erythematous nodules, fever, and systemic features.

Q22. What is the WHO disability grading system referenced (Grade 1/Grade 2)? A: Grade 0 = no disability. Grade 1 = loss of protective sensation in hands/feet or eyes without visible deformity. Grade 2 = visible deformity or damage present (e.g., clawing, ulcers, lagophthalmos, corneal opacity) - used as a program indicator of late diagnosis/treatment delay.

Q23. Both studies had "no funding/no conflicts of interest" - why does that matter to a journal club audience? A: It reduces (though doesn't eliminate) concern about sponsor-driven bias in design or reporting, which is particularly relevant for diagnostic-test-comparison and vaccine-related studies where commercial serology-kit manufacturers or vaccine producers could otherwise have a stake in favorable results.

Q24. If you were to design a follow-up study addressing these limitations, what would you do differently? A: Multi-center, adequately powered prospective design; documented BCG vaccination card/registry data rather than scar as proxy; standardized reaction and disability grading with blinded assessors; multivariate regression adjusting for age, contact intensity, nutritional status, and genetic susceptibility (e.g., HLA typing); and for the diagnostic-accuracy paper, inclusion of PCR/qPCR for M. leprae DNA as an additional reference/comparator, plus paired sampling (SSS + serology + biopsy) in every patient.

A quick honesty note: a few numeric details your consultants may drill into (exact p-values, ROC AUC with 95% CI, and the SSS/APGL-I sensitivity-specificity percentages) weren't fully legible/complete in the results table images embedded in your slides. I'd recommend pulling up Table 2/3 and the ROC statistics table from the original papers before your presentation so you can quote the exact numbers if pressed - I've flagged those specific spots above (Q6, Q9, Q15) as the ones most likely to get a "what was the actual number/p-value" follow-up.

AS A PRESENTER I WOULD BE STATING A COMMENT FOR EACH OF THE STUDIES PRESENTED HELP ME WITH THAT COMMENT

Here's a presenter's closing comment for each study - the kind of concise, critical-appraisal statement you'd deliver right after your discussion/conclusion slide, before moving to the next paper.

Comment on Study 1: BCG Vaccination in Childhood Leprosy (PGIMER)

"In my opinion, this study is valuable because it comes from a large tertiary-care leprosy referral center with nearly a decade of data, and it adds to the relatively sparse literature specifically looking at BCG's role in childhood leprosy rather than tuberculosis. The finding that absence of a BCG scar was significantly associated with lepromatous-pole disease is biologically plausible, given BCG's known immunomodulatory effect of favoring a Th1/cell-mediated response, and it reinforces the broader hypothesis that BCG may not just prevent leprosy but also shift its clinical spectrum toward the milder, paucibacillary end. However, I'd interpret these findings cautiously - it is a retrospective, single-center study with a small sample size of just 50 children, and only 11 were BCG-scar-negative, so the subgroup comparisons driving the key conclusion are based on very limited numbers. The use of BCG scar as a surrogate for vaccination status is also a real methodological weakness, since scar failure occurs in up to 1-20% of truly vaccinated individuals, which could dilute or even misclassify the association. There's also no mention of adjustment for confounders like nutritional status, degree of household contact, or genetic susceptibility, all of which independently influence disease spectrum. So overall, I'd say this study generates a hypothesis worth pursuing rather than establishing a definitive protective effect, and it highlights the need for larger, prospective, multi-center studies with documented vaccination records before we can draw firm conclusions."

Comment on Study 2: Slit Skin Smear vs Anti-PGL-I Serology

"I found this study useful because it directly addresses a real clinical gap, that is, our over-reliance on slit-skin smear despite its known poor sensitivity, especially in early or paucibacillary disease. The result that anti-PGL-I serology outperformed SSS in detecting smear-negative paucibacillary cases is consistent with what we'd expect biologically, since PGL-I is a bacillary-load-dependent marker and SSS depends on directly visualizing scant bacilli. The ROC curve analysis strengthens their comparison by giving an objective, threshold-independent measure of diagnostic performance rather than relying on a single sensitivity/specificity cutoff. That said, the study is cross-sectional and single-center, done in patients already clinically suspected of leprosy, so there's a risk of spectrum bias, and these accuracy figures may not translate directly to population-level screening or asymptomatic contact screening. Restricting the serology to IgM anti-PGL-I alone is another limitation, since other isotypes or combined panels might further improve performance. Practically, I don't think this study argues for replacing SSS, since SSS still offers higher specificity and is cheap and field-deployable, but rather supports using anti-PGL-I as a sequential adjunct test, particularly for smear-negative but clinically suspicious paucibacillary patients, to reduce missed or delayed diagnoses."

Feel free to shorten either of these if your slot is time-limited - the key sentence to keep in each is the middle one (biological plausibility) and the last one (practical takeaway), since those are the ones consultants tend to nod along to and rarely challenge further.

GIVE A BETTER MORE OF A CRITICAL COMMENT

Here are sharper, more critical versions - written the way a tough consultant would want to hear you push back on the papers rather than just summarize them.

Critical Comment: Study 1 (BCG in Childhood Leprosy, PGIMER)

"My honest critical appraisal is that this study overreaches on its central claim. The entire conclusion about BCG's protective effect rests on comparing 11 scar-negative children against 39 scar-positive children, and BCG scar is a poor surrogate for actual vaccination status, with documented scar-failure rates of 1-20%. That means some of the 11 'unvaccinated' children in the lepromatous group may well have been vaccinated, and we have no way to know how many, since there was no verification against immunization cards or Anganwadi/health records. This is a fundamental design flaw, not a minor caveat, because it directly affects the exposure variable the whole hypothesis depends on.

Second, this is a retrospective chart review spanning nearly ten years at a single tertiary center, which means it captures a highly selected, referral-biased population, likely sicker or more complicated cases than what you'd see in the community, and they've explicitly excluded incomplete records, stacking further selection bias on top. Ten years of practice also means diagnostic criteria, smear reading, and even MDT protocols could have drifted, and none of that is accounted for.

Third, there is no correction for confounding. Nutritional status, intensity and duration of household contact, and genetic susceptibility (HLA-DR2/DR3 associations with disease spectrum are well documented) are all known determinants of whether someone develops paucibacillary or multibacillary disease, and none of these were adjusted for. So the 'BCG protects against MB disease' conclusion could just as easily be confounded by unvaccinated children coming from poorer, more crowded households with heavier bacillary exposure, since BCG coverage itself tracks with healthcare access and socioeconomic status.

Finally, with only 6 total reaction events and 11 disability events in the whole cohort, any subgroup statistics on reactions or disability by vaccination status are essentially underpowered noise, not a reliable signal. I'd tell my consultants that this paper is worth discussing because it raises a plausible immunological hypothesis, but as evidence it's weak, hypothesis-generating at best, and shouldn't change practice or counseling on its own."

Critical Comment: Study 2 (SSS vs Anti-PGL-I Serology)

"Critically, I think this paper overstates how 'novel' or practice-changing its finding is. That anti-PGL-I serology outperforms SSS in paucibacillary, low-bacillary-load disease is already well established in the literature going back decades, so this cross-sectional study from a single center is really just a local confirmatory exercise, not new knowledge, and the discussion section itself concedes this by saying results 'run parallel to broader systematic reviews.'

More importantly, this is a cross-sectional study done exclusively in patients who were already clinically suspected of leprosy, so we're only testing diagnostic accuracy in a pre-selected, symptomatic population. That inflates apparent performance for both tests through spectrum bias, since we know sensitivity and specificity are not fixed test properties, they shift with disease-spectrum severity in the sample. These numbers cannot be extrapolated to screening asymptomatic household contacts or subclinical infection, which is arguably the more clinically important use-case for a serological test like this.

The exclusion criteria also concern me: excluding anyone already treated for more than 3 months and anyone with lepra reactions cherry-picks a cleaner, more 'textbook' population, which again inflates the diagnostic performance figures relative to real-world clinical uncertainty where reactions and partially treated cases are common referral scenarios.

There's also a methodological gap they don't adequately address: no molecular gold standard. Without PCR-based M. leprae DNA detection as a reference or tie-breaker, both SSS and serology are being compared against a clinical/histopathological composite reference that itself has known limitations, particularly the ~35% confirmation rate on histopathology they cite. So the 'true' sensitivity and specificity numbers for both tests are only as good as an imperfect reference standard, and that limitation isn't factored into their statistical analysis.

Lastly, restricting to IgM alone and using a single manufacturer's ELISA kit means these accuracy figures are assay-specific and may not generalize to other anti-PGL-I platforms with different cutoffs. My overall take is that this confirms known biology in a new geographic setting, but I wouldn't call it strong practice-changing evidence, and the 'add anti-PGL-I as an adjunct' recommendation, while reasonable, isn't really justified by anything new in this dataset."

If you want, I can also prep 1-2 line rebuttals in case a consultant pushes back and says "but isn't confirmatory data from a new population still useful?" - that's a common counter they'll throw back at a harsh critique like this.

What are the recent studies and there outcome about anti pgl1 in leprosy

Reading File

Searching PubMed

"anti-PGL-I" OR "phenolic glycolipid" leprosy diagnosis

Searching PubMed

"PGL-I" seropositivity household contacts leprosy

Searching PubMed

anti-PGL-I leprosy relapse OR prognosis

Reading Article

PMID: 40435099

Reading Article

PMID: 39520505

Reading Article

PMID: 37828950

Reading Article

PMID: 36993802

Reading Article

PMID: 41551453

Reading Article

PMID: 37231779

Recent Studies on Anti-PGL-I in Leprosy (last ~3 years)

The literature has shifted anti-PGL-I's main use case away from "diagnosing established leprosy" (where SSS/serology comparisons like your journal club paper sit) and toward risk-stratifying and monitoring household contacts / transmission, which is where most of the newer papers are concentrated.

1. Household contact risk-stratification (largest cluster of new evidence)

Niitsuma et al., 2025 (Brazil, Mem Inst Oswaldo Cruz) [PMID: 40435099] - Cohort of 629 contacts followed 1998-2018 in a hyperendemic Brazilian region. Living with a multibacillary (MB) patient raised the odds of anti-PGL-I seropositivity 3-fold (OR 3.01), and living with a patient who had Grade II disability raised it 4.4-fold (OR 4.43). Actual leprosy development was driven by shared residence (OR 2.84) and blood relation to the index case (OR 2.56); 98% of contacts who developed leprosy had lived with more than one leprosy patient. Outcome: bacillary load and disability grade of the index case, not just contact status, predict seroconversion risk.

Salah et al., 2024 (Egypt, Arch Dermatol Res) [PMID: 39520505] - Same group/setting as your assigned SSS-vs-serology paper. In household contacts, anti-PGL-I IgM titers were significantly higher when >4 people shared a room with the index case (p=0.032) and when the index case had disabilities or nerve damage (p=0.001). A cutoff of 0.1 gave 75% sensitivity/54.5% specificity (72.3% accuracy) for identifying exposed contacts. Outcome: anti-PGL-I is being repositioned as an exposure/infection-risk marker in contacts, not just a patient-diagnostic test.

Khariri et al., 2026 (Indonesia, PeerJ) [PMID: 41551453] - 320 household contacts; 43.8% were anti-PGL-I seropositive. Interestingly, documented BCG vaccination history lowered odds of seropositivity (aOR 0.514), but a visible BCG scar was paradoxically associated with higher odds (aOR 1.95) - the authors call this a "complex interaction" needing standardized scar-assessment methodology. This is directly relevant to your BCG paper's use of scar-as-proxy critique.

Serrano-Coll et al., 2023 (Colombia) [PMID: 37231779, Evidence tier 5 - observational] - 428 household contacts tested for anti-NDO-LID (a semisynthetic PGL-I mimic) antibodies: 36.9% IgM, 28.3% IgG seropositive, no difference between PB vs MB contact groups. Concludes ongoing active transmission in Colombia despite "elimination" status - a good parallel to your paper's discussion point about India's plateauing childhood-leprosy proportion.

2. Transmission surveillance in children

Pierneef et al., 2023 (Bihar, India, Frontiers in Medicine) [PMID: 37828950] - Field-friendly fingerstick anti-PGL-I lateral flow assay in 1,857 children (age 3-11) in endemic villages: 11.58% seropositive, consistent with historical benchmarks. Proposed as a low-complexity tool to monitor recent transmission at the community level, directly relevant to childhood leprosy control programs (ties into your first paper's PGIMER pediatric population).

3. Using seropositivity to trigger early neurological workup

Dos Santos et al., 2023 (Brazil) [PMID: 36993802] - In 361 anti-PGL-I-seropositive but asymptomatic contacts, electroneuromyography found subclinical neural impairment in 23.5%, while only 25.9% of those with abnormal nerve conduction had any clinical nerve thickening on exam. Outcome: seropositivity alone is a trigger to justify deeper (EMG/qPCR) workup, since clinical exam under-detects early neuropathy.

Luppi et al., 2023 [PMID: 37220153] - Companion study using high-resolution ultrasonography for the same purpose in seropositive contacts, supporting nerve ultrasound as an early, non-invasive detection tool.

4. Antibody isotype refinement (methodological)

Albuquerque et al., 2022 [PMID: 34974816] - Investigated whether different anti-PGL-I isotypes (IgM/IgG/IgA) can distinguish leprosy patients from exposed-but-healthy contacts, directly addressing the limitation you flagged in your Egyptian paper about restricting to IgM alone.

What this means for your presentation

Taken together, these recent (2022-2026) studies show the field moving in a direction slightly different from your assigned SSS-vs-anti-PGL-I paper: the newer emphasis is not "which test diagnoses existing leprosy better" but "can anti-PGL-I identify subclinical/high-risk contacts before they become symptomatic," with downstream use for prophylaxis (e.g., single-dose rifampicin, per the linked 2023 NEJM correspondence on rifapentine in household contacts [PMID: 37585641/37585642]) or triggering nerve-conduction studies. This is a stronger, more clinically actionable direction than pure diagnostic-accuracy comparison, and it's a good point to raise if a consultant asks "so what's next for this biomarker" - you can say the field has largely moved toward contact screening and transmission surveillance rather than replacing SSS in symptomatic patients.

One honesty caveat: nearly all of these are cross-sectional or cohort observational studies (evidence tier 5/9), not RCTs or systematic reviews - I did not find a recent meta-analysis specifically pooling anti-PGL-I diagnostic accuracy data. So while the direction of evidence is fairly consistent, the certainty level for consultants pressing on "how strong is this evidence" is still moderate-to-low.

This is a shared conversation. Sign in to Orris to start your own chat.